BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program

NEXT STORY
Rapid Test Market To Reach USD 48.54 Billion By 2026 | Reports And Data
PREV STORY
BioAegis Therapeutics Announces Publication: “Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza”
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

author_avatar
NASDAQ Market News

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination ...

author_avatar
NASDAQ Market News

NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors

author_avatar
NASDAQ Market News